AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Drug Interaction Study Between AZD3480 and Cytochrome P450
Phase 1
Completed
- Conditions
- MetabolismAlzheimer's Disease
- Interventions
- Drug: PlaceboDrug: Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2008-11-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00692510
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2008-06-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00692042
- Locations
- 🇬🇧
Reserach Site, Macclesfield, Cheshire, United Kingdom
Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex Therapy
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1646
- Registration Number
- NCT00692874
- Locations
- 🇭🇺
Research Site, Zalaegerszeg, Hungary
Spanish Validation of Tool Questionnaire to Assess Patients´Perception About Antipsychotic Treatment
Completed
- Conditions
- SchizophreniaBipolar Disorder
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT00692133
- Locations
- 🇪🇸
Research Site, Tarragona, Spain
Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1510
- Registration Number
- NCT00692289
- Locations
- 🇭🇺
Research Site, Zalaegerszeg, Hungary
Predictors of Recurrence in Bipolar Disorder in Spain
Completed
- Conditions
- Bipolar Disorder
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 595
- Registration Number
- NCT00690859
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Upper GI Symptoms In Patients Receiving Acetylsalicylic Acid/NSAIDs - NSAIDs Wave 2
Completed
- Conditions
- Upper-GI Symptoms
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2009-01-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 850
- Registration Number
- NCT00691743
- Locations
- 🇬🇷
Research Site, Xania, Greece
Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers
Completed
- Conditions
- Bipolar Disorder
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2008-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 540
- Registration Number
- NCT00691353
- Locations
- 🇬🇷
Research Site, Thiva, Greece
Electronic Health Record (EHR)-Based Intervention for Gastroesophageal Reflux Disease (GERD) and Chronic Non-steroidal Anti-inflammatory Drug (NSAID) Use
Completed
- Conditions
- GERD
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5234
- Registration Number
- NCT00691171
Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2014-01-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 118
- Registration Number
- NCT00690482
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
© Copyright 2025. All Rights Reserved by MedPath